Amneal Pharmaceuticals LLC.

Company Snapshot

Founded: 2002
Entity Type: Public
Employees: 8,100
Region: U.S.
Revenue: $2,794.0 Millions
Revenue Year: 2024
Headquarter: New Jersey, U.S.
Key Geographics: U.S., Europe, South East Asia, Middle East and Africa
Corporate Address: 400 Crossing Boulevard, Bridgewater, New Jersey 08807 U.S. Tel. +1-908-947-3120 www.amneal.com

Company Overview

Amneal Pharmaceuticals, is a global pharmaceutical company specializing in developing, manufacturing, and distributing a broad range of generic and specialty pharmaceutical products. With a diverse portfolio that includes generics, injectables, biosimilars, and specialty brands, Amneal operates mainly across the United States, India, and Ireland. The company’s product lineup addresses essential therapeutic needs, focusing on central nervous system disorders, complex generics, and biosimilars. Amneal’s commitment to innovation is evident in its robust R&D pipeline, while its AvKARE segment supplies the U.S. government and various institutions, enhancing Amneal’s role in delivering affordable healthcare solutions.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Amneal Pharmaceuticals LLC. In Reports

Brain Tumor Therapeutics: Global Markets to 2030

According to BCC Research detailed report on brain tumor therapeutics market report analyzes the market trends of brain tumor therapeutics with data from 2024, estimates from 2025 compound annual growth rates through...

Anti-Parkinson's Drugs: Global Markets to 2030

BCC Research Market Analyst says global market for anti-Parkinson’s drugs is projected to grow from $6.1 billion in 2025 to reach $9.2 billion by the end of 2030, at a CAGR of 8.6%.

Biosimilars: Global Markets

BCC Research Report: Dive into biosimilars market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, and forecast for 2029.

Company's Business Segments

  • Affordable Medicines : Affordable Medicines Segment Includes Retail Generics, Injectables, And Biosimilars.
  • Specialty : Offer a Portfolio of Branded Pharmaceuticals Focused Primarily on Central Nervous System and Endocrine Disorders.
  • AvKARE : Distributor of Pharmaceuticals and Other Products For The U.S. Federal Government, Retail, Institutional Markets.

Applications/End User Industries

  • Pharmaceutical
  • Hospitals
  • Healthcare
  • Generics
  • Biosimilars
  • Central Nervous System
  • Endocrine Disorders
  • Injectables
AI Sentiment